Apogee Therapeutics, Inc. (APGE)

USD 44.69

(-7.07%)

Market Cap (In USD)

2.61 Billion

Revenue (In USD)

-

Net Income (In USD)

-83.98 Million

Avg. Volume

450.22 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
24.88-72.29
PE
-
EPS
-
Beta Value
2.3247926
ISIN
US03770N1019
CUSIP
03770N101
CIK
1974640
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Michael Thomas Henderson M.D.
Employee Count
-
Website
https://www.apogeetherapeutics.com
Ipo Date
2023-07-14
Details
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.